Navigation Links
Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
Date:7/16/2008

-- Federal Court Enters Consent Judgment Terminating Litigation --

MADISON, N.J., July 16 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR(R) antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective today.

Under the terms of the settlement, Wyeth has granted Impax a license that would permit Impax to launch its capsule formulation of Effexor XR on or after June 1, 2011, subject to earlier launch in limited circumstances, but in no event earlier than January 1, 2011. Impax will pay Wyeth a royalty on sales of this generic product.

The parties also have agreed that Impax will utilize its neurology-focused sales force to promote a product to be named by Wyeth. Other terms of this agreement are confidential and were not disclosed.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost- containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeths Motion to Overturn Punitive Damages Award Granted by Arkansas Court
2. Wyeth Announces Bernard Poussot Assumes Chairman of the Board Position
3. Wyeth Declares Common and Preferred Stock Dividends
4. Wyeth Pharmaceuticals Announces Organizational Change
5. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
6. Wyeth to Present at the 2008 Citi Investment Research Global Healthcare Conference
7. Wyeth Research Head Robert R. Ruffolo, Jr., Ph.D., Announces Retirement
8. Wyeth Chairman Robert Essner Announces June 27 Retirement
9. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
10. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
11. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Noom Inc. , the leader ... offer fully Spanish behavior change programs that address ... prevention and healthy weight management programs  have ... interventions among Hispanic Americans who are at increased ... database, program-specific curriculum content and program features are ...
(Date:1/17/2017)... , Jan. 17, 2017  Northwell Health ... the advance of precision cancer research. ... largest health care provider, Northwell Health diagnoses ... Indivumed, GmbH is a Germany ... medical therapies. Together they will greatly expand cancer ...
(Date:1/17/2017)... Boston, MA (PRWEB) , ... January 17, 2017 ... ... of the completely re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment ... be validating these new tools and assays, and their applicability in drug safety ...
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, ... that it has initiated a global Phase 2b ... oral peptide that targets alpha4beta7 integrin. The aim ... is to evaluate the safety/tolerability and efficacy of ... with moderate to severe active disease. ...
Breaking Biology Technology:
(Date:12/16/2016)... 2016 Research and Markets has announced the ... Forecast to 2021" report to their offering. ... The biometric vehicle access system ... CAGR of 14.06% from 2016 to 2021. The market is estimated ... reach 854.8 Million by 2021. The growth of the biometric vehicle ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much more ... or starting the engine. Continental will demonstrate the intelligence ... Las Vegas . Through the combination of the ... Entry) and biometric elements, the international technology company is ... personalization and authentication. "The integration of biometric ...
Breaking Biology News(10 mins):